Considerations for Intravenous Anesthesia Dose in Obese Children: Understanding PKPD
暂无分享,去创建一个
[1] P. Ramnarayan,et al. Optimising intravenous salbutamol in children: a phase 2 study , 2022, Archives of Disease in Childhood.
[2] V. Conti,et al. Drug dosing in children with obesity: a narrative updated review , 2022, Italian Journal of Pediatrics.
[3] D. Greenblatt,et al. Drug Disposition in Subjects With Obesity: The Research Work of Darrell R. Abernethy , 2022, Journal of clinical pharmacology.
[4] B. Anderson,et al. Pharmacokinetic Pharmacodynamic Modelling Contributions to Improve Paediatric Anaesthesia Practice , 2022, Journal of clinical medicine.
[5] B. Anderson,et al. Population Pharmacokinetic Modelling of Acetaminophen and Ibuprofen: the Influence of Body Composition, Formulation and Feeding in Healthy Adult Volunteers , 2022, European Journal of Drug Metabolism and Pharmacokinetics.
[6] N. Holford,et al. Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates , 2021, Journal of Pharmacokinetics and Pharmacodynamics.
[7] J. Hannam,et al. Population pharmacokinetics of oxycodone: Premature neonates to adults , 2021, Paediatric anaesthesia.
[8] B. Anderson,et al. Estimation of the Loading Dose for Target-Controlled Infusion of Dexmedetomidine. Reply to Eleveld et al. Comment on “Morse et al. A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults. J. Clin. Med. 2020, 9, 3480” , 2021, Journal of Clinical Medicine.
[9] R. ter Heine,et al. Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies , 2020, European Journal of Clinical Pharmacology.
[10] B. Anderson,et al. A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults , 2020, Journal of clinical medicine.
[11] N. Holford,et al. TDM is dead. Long live TCI! , 2020, British journal of clinical pharmacology.
[12] J. Sear,et al. Pharmacokinetic and Pharmacodynamic Analysis of Alfaxalone Administered as a Bolus Intravenous Injection of Phaxan in a Phase 1 Randomized Trial , 2020, Anesthesia and analgesia.
[13] J. Clarke,et al. Ideal body weight in the precision era: recommendations for prescribing in obesity require thought for computer-assisted methods , 2019, Archives of Disease in Childhood.
[14] J. Hannam,et al. A manual propofol infusion regimen for neonates and infants , 2019, Paediatric anaesthesia.
[15] J. Standing,et al. Optimizing clonidine dosage for sedation in mechanically ventilated children: A pharmacokinetic simulation study , 2019, Paediatric anaesthesia.
[16] A. Darzi,et al. Assessing the Agreement of 5 Ideal Body Weight Calculations for Selecting Medication Dosages for Children With Obesity. , 2019, JAMA pediatrics.
[17] Ricardo Fuentes,et al. Propofol pharmacokinetic and pharmacodynamic profile and its electroencephalographic interaction with remifentanil in children , 2018, Paediatric anaesthesia.
[18] B. Anderson,et al. Effect-Site Target-Controlled Infusion in the Obese: Model Derivation and Performance Assessment , 2018, Anesthesia and analgesia.
[19] J. Chávez-Pacheco,et al. Population Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Children Undergoing Ambulatory Surgery , 2018, Anesthesia and analgesia.
[20] M. Struys,et al. Pharmacokinetic–pharmacodynamic model for propofol for broad application in anaesthesia and sedation , 2018, British journal of anaesthesia.
[21] A. S. Leung,et al. Pharmacokinetic and pharmacodynamic study of intranasal and intravenous dexmedetomidine , 2018, British journal of anaesthesia.
[22] Bruno Reichart,et al. Does size matter? , 2018, Xenotransplantation.
[23] Stephen B. Duffull,et al. A Review of the Methods and Associated Mathematical Models Used in the Measurement of Fat-Free Mass , 2018, Clinical Pharmacokinetics.
[24] N. Holford,et al. What is the best size predictor for dose in the obese child? , 2017, Paediatric anaesthesia.
[25] M. Struys,et al. Dexmedetomidine pharmacokinetic–pharmacodynamic modelling in healthy volunteers: 1. Influence of arousal on bispectral index and sedation , 2017, British journal of anaesthesia.
[26] M. Struys,et al. An Allometric Model of Remifentanil Pharmacokinetics and Pharmacodynamics , 2017, Anesthesiology.
[27] N. Holford,et al. Allometric size: The scientific theory and extension to normal fat mass , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[28] Nick Holford,et al. Theory‐based pharmacokinetics and pharmacodynamics of S‐ and R‐warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients , 2017, British journal of clinical pharmacology.
[29] K. Matson,et al. Medication Dosage in Overweight and Obese Children. , 2017, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.
[30] N. Holford,et al. Getting the dose right for obese children , 2016, Archives of Disease in Childhood.
[31] H. Collier,et al. Prescribing in obese children: how good are paediatricians? , 2016, Archives of Disease in Childhood.
[32] N. Holford,et al. Salbutamol has rapid onset pharmacodynamics as a bronchodilator , 2016, Acta Anaesthesiologica Scandinavica.
[33] Stephen Duffull,et al. Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients. , 2016, British journal of clinical pharmacology.
[34] J. Frazier,et al. Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics , 2016, Clinical Pharmacokinetics.
[35] N. Holford,et al. Dexmedetomidine pharmacokinetics in the obese , 2015, European Journal of Clinical Pharmacology.
[36] T. Inge,et al. Population pharmacokinetic–pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents , 2015, Paediatric anaesthesia.
[37] J. Berkenbosch,et al. The impact of obesity on pediatric procedural sedation‐related outcomes: results from the Pediatric Sedation Research Consortium , 2015, Paediatric anaesthesia.
[38] Hesham S. Al-Sallami,et al. Prediction of Fat-Free Mass in Children , 2015, Clinical Pharmacokinetics.
[39] M. Struys,et al. Propofol Breath Monitoring as a Potential Tool to Improve the Prediction of Intraoperative Plasma Concentrations , 2015, Clinical Pharmacokinetics.
[40] J. Jankiewicz-Wika,et al. Reduced plasma level of diazepam-binding inhibitor (DBI) in patients with morbid obesity , 2015, Endocrine.
[41] M. Görges,et al. Identifying a rapid bolus dose of dexmedetomidine (ED50) with acceptable hemodynamic outcomes in children , 2014, Paediatric anaesthesia.
[42] Michel M. R. F. Struys,et al. A General Purpose Pharmacokinetic Model for Propofol , 2014, Anesthesia and analgesia.
[43] J. Barrett,et al. Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization , 2013, Clinical Cancer Research.
[44] A. Åsberg,et al. Importance of hematocrit for a tacrolimus target concentration strategy , 2013, European Journal of Clinical Pharmacology.
[45] Nick Holford,et al. A pharmacokinetic standard for babies and adults. , 2013, Journal of pharmaceutical sciences.
[46] N. Holford,et al. Understanding dosing: children are small adults, neonates are immature children , 2013, Archives of Disease in Childhood.
[47] T. Merriman,et al. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout , 2013, European Journal of Clinical Pharmacology.
[48] T. Inge,et al. Propofol clearance in morbidly obese children and adolescents: influence of age and body size. , 2012, Clinical pharmacokinetics.
[49] B. Anderson. My child is unique; the pharmacokinetics are universal , 2012, Paediatric anaesthesia.
[50] J. Beijnen,et al. Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis , 2012, Antimicrobial Agents and Chemotherapy.
[51] M. Jamei,et al. Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients , 2011, Clinical pharmacokinetics.
[52] M. Struys,et al. Obesity and Allometric Scaling of Pharmacokinetics , 2011, Clinical Pharmacokinetics.
[53] J. Brodsky,et al. Lean Body Weight Scalar for the Anesthetic Induction Dose of Propofol in Morbidly Obese Subjects , 2011, Anesthesia and analgesia.
[54] T. Lauritsen,et al. Anesthetizing the obese child , 2011, Paediatric anaesthesia.
[55] H. Lemmens,et al. Dose adjustment of anaesthetics in the morbidly obese. , 2010, British journal of anaesthesia.
[56] M. Struys,et al. Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. , 2010, British journal of anaesthesia.
[57] H. Lemmens. Perioperative pharmacology in morbid obesity , 2010, Current opinion in anaesthesiology.
[58] H. Mulla,et al. Dosing dilemmas in obese children , 2010, Archives of Disease in Childhood: Education & Practice Edition.
[59] A. Dahan,et al. Propofol Reduces the Distribution and Clearance of Midazolam , 2010, Anesthesia and analgesia.
[60] B. Anderson,et al. Are there still limitations for the use of target-controlled infusion in children? , 2010, Current opinion in anaesthesiology.
[61] G. Warman,et al. Dexmedetomidine hemodynamics in children after cardiac surgery , 2010, Paediatric anaesthesia.
[62] M. H. Ensom,et al. Pharmacokinetics and drug dosing in obese children. , 2010, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.
[63] N Holford,et al. Dosing in Children , 2010, Clinical pharmacology and therapeutics.
[64] B. Anderson. Pediatric models for adult target‐controlled infusion pumps , 2010, Paediatric anaesthesia.
[65] J. Standing,et al. Pharmacokinetic–pharmacodynamic modeling of the hypotensive effect of remifentanil in infants undergoing cranioplasty , 2010, Paediatric anaesthesia.
[66] N. Holford,et al. Leaving no stone unturned, or extracting blood from stone? , 2010, Paediatric anaesthesia.
[67] L. Rasmussen,et al. Should Dosing of Rocuronium in Obese Patients Be Based on Ideal or Corrected Body Weight? , 2009, Anesthesia and analgesia.
[68] A. Dahan,et al. Mixed-Effects Modeling of the Influence of Midazolam on Propofol Pharmacokinetics , 2009, Anesthesia and analgesia.
[69] M. Coulthard,et al. Human renal function maturation: a quantitative description using weight and postmenstrual age , 2009, Pediatric Nephrology.
[70] N. Holford,et al. Mechanistic basis of using body size and maturation to predict clearance in humans. , 2009, Drug metabolism and pharmacokinetics.
[71] L. Colla,et al. Pharmacokinetic Model-Driven Remifentanil Administration in the Morbidly Obese , 2009, Clinical pharmacokinetics.
[72] B. Goh,et al. Does saturable formation of gemcitabine triphosphate occur in patients? , 2008, Cancer Chemotherapy and Pharmacology.
[73] N. Holford,et al. Mechanism-based concepts of size and maturity in pharmacokinetics. , 2008, Annual review of pharmacology and toxicology.
[74] S. Duffull,et al. Dosing in Obesity: A Simple Solution to a Big Problem , 2007, Clinical pharmacology and therapeutics.
[75] T. Stephenson. How children's responses to drugs differ from adults. , 2005, British journal of clinical pharmacology.
[76] A. Casati,et al. Anesthesia in the obese patient: pharmacokinetic considerations. , 2005, Journal of clinical anesthesia.
[77] Stephen B. Duffull,et al. Quantification of Lean Bodyweight , 2005, Clinical pharmacokinetics.
[78] T. Pellis,et al. The Effects of Cisatracurium on Morbidly Obese Women , 2004, Anesthesia and analgesia.
[79] T. Pellis,et al. The Pharmacodynamic Effects of Rocuronium When Dosed According to Real Body Weight or Ideal Body Weight in Morbidly Obese Patients , 2004, Anesthesia and analgesia.
[80] S. Duffull,et al. What is the best size descriptor to use for pharmacokinetic studies in the obese? , 2004, British journal of clinical pharmacology.
[81] N. Holford,et al. Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. , 2004, British journal of clinical pharmacology.
[82] C. Kirkpatrick,et al. A Standard Weight Descriptor for Dose Adjustment in the Obese Patient , 2004, Clinical pharmacokinetics.
[83] L. Brennan,et al. Childhood obesity: a challenge for the anaesthetist? , 2002, Paediatric anaesthesia.
[84] G. Meakin,et al. Scaling for size: some implications for paediatric anaesthesia dosing , 2002, Paediatric anaesthesia.
[85] N. Holford,et al. Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy , 2001, European Journal of Clinical Pharmacology.
[86] R. Brolin,et al. Efficacy and Safety of Patient-Controlled Analgesia for Morbidly Obese Patients Following Gastric Bypass Surgery , 2000, Obesity surgery.
[87] J Schüttler,et al. Population Pharmacokinetics of Propofol: A Multicenter Study , 2000, Anesthesiology.
[88] S L Shafer,et al. The influence of age on propofol pharmacodynamics. , 1999, Anesthesiology.
[89] E Olofsen,et al. The dynamic relationship between end-tidal sevoflurane and isoflurane concentrations and bispectral index and spectral edge frequency of the electroencephalogram. , 1999, Anesthesiology.
[90] T. Short,et al. The use of propofol infusions in paediatric anaesthesia: a practical guide , 1999, Paediatric anaesthesia.
[91] T. Egan,et al. Remifentanil Pharmacokinetics in Obese versus Lean Patients , 1998, Anesthesiology.
[92] D. R. Wada,et al. Determination of the Distribution Volume that can be Used to Calculate the Intravenous Loading Dose , 1998, Clinical pharmacokinetics.
[93] N. Holford,et al. Size, Myths and the Clinical Pharmacokinetics of Analgesia in Paediatric Patients , 1997, Clinical pharmacokinetics.
[94] James H. Brown,et al. A General Model for the Origin of Allometric Scaling Laws in Biology , 1997, Science.
[95] Nicholas H. G. Holford,et al. A Size Standard for Pharmacokinetics , 1996, Clinical pharmacokinetics.
[96] J. Whitwam,et al. Flumazenil and midazolam in anaesthesia , 1995, Acta anaesthesiologica Scandinavica. Supplementum.
[97] N H Holford,et al. The Target Concentration Approach to Clinical Drug Development , 1995, Clinical pharmacokinetics.
[98] D. Morgan,et al. Lean Body Mass as a Predictor of Drug Dosage , 1994, Clinical pharmacokinetics.
[99] S. Gatt,et al. Epidural Catheters for Obstetrics: Terminal Hole or Lateral Eyes? , 1994, Regional Anesthesia & Pain Medicine.
[100] R. Farinotti,et al. Propofol Infusion for Maintenance of Anesthesia in Morbidly Obese Patients Receiving Nitrous Oxide A Clinical and Pharmacokinetic Study , 1993, Anesthesiology.
[101] R. Matteo,et al. Pharmacokinetics and Pharmacodynamics of Vecuronium in the Obese Surgical Patient , 1992, Anesthesia and analgesia.
[102] D. Greenblatt,et al. Prolonged Accumulation of Diazepam in Obesity , 1983, Journal of clinical pharmacology.
[103] G. Forbes,et al. Lean body mass in obesity. , 1983, International journal of obesity.
[104] D. Greenblatt,et al. Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). , 1982, Journal of pharmaceutical sciences.
[105] D. Greenblatt,et al. Digoxin disposition in obesity: clinical pharmacokinetic investigation. , 1981, American heart journal.
[106] T. Lohman. Skinfolds and body density and their relation to body fatness: a review. , 1981, Human biology.
[107] U. Klotz,et al. Pathophysiological and Disease-Induced Changes in Drug Distribution Volume: Pharmacokinetic Implications , 1976, Clinical pharmacokinetics.
[108] B. Groves,et al. Digoxin Metabolism in Obesity , 1971, Circulation.
[109] B. Friis‐Hansen. Body composition during growth. In vivo measurements and biochemical data correlated to differential anatomical growth. , 1971, Pediatrics.
[110] A. Keys,et al. Body fat in adult man. , 1953, Physiological reviews.
[111] D. D. Bois,et al. CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .